As previously reported, Barclays upgraded Roche (RHHBY) to Overweight from Equal Weight with a CHF 390 price target as the firm transferred coverage of European large-cap pharma to a new analyst. The firm cites an “attractive” setup on 2026 clinical catalysts as well as a “strong” operational outlook and “undemanding” valuation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche upgraded to Overweight from Equal Weight at Barclays
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- Government deals lift overhang on pharma group, says BofA
- Genentech announces FDA approval of CD20xCD3 bispecific Lunsumio Velo